Multidisciplinary Care for Vitiligo: Beyond Dermatology

This episode, "Multidisciplinary Care for Vitiligo: Beyond Dermatology," expands the care team beyond dermatology to address the full weight of vitiligo.

Dr. Desai describes vitiligo management as inherently multidisciplinary, starting with close coordination with a patient's primary care provider whenever a metabolic abnormality is present. He also loops in an endocrinologist when there is an underlying thyroid or other endocrine issue, and he is comfortable deferring to that specialist's judgment, even when the note back simply confirms mildly abnormal antibodies do not need active monitoring. He explains that the specialist he consults most often, more frequently than an endocrinologist, is a clinical psychologist or psychiatrist, because so many of his vitiligo patients carry significant psychological distress alongside their skin disease. In pediatric cases, he adds a pediatrician to help manage anxiety in children and their families, reflecting how broadly the disease's burden extends beyond dermatology alone.

Dr. Hamzavi agrees with that approach and adds one more resource: patient support groups. He points out that access to mental health care remains difficult even for patients with insurance, and that limited income compounds the problem for many of the populations he and his colleagues treat. In that context, he argues, support groups become especially valuable, since the stigmatization that surrounds vitiligo is itself a distinct mental-health burden that peer support can help attenuate. Taken together, the panelists frame multidisciplinary coordination, spanning primary care, endocrinology, psychology or psychiatry, pediatrics, and community support networks, as a core part of standard vitiligo care rather than an optional add-on, particularly for patients whose disease carries heavy psychosocial weight on top of its visible physical effects and functional impact on daily life.

The next episode in this series, "First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy," moves into treatment, starting with the panel's first-line options.

This video was supported independently by Pfizer.